Relative importance of central imidazoline receptors for the antihypertensive effects of moxonidine and rilmenidine

Journal of Hypertension

Volumn 14, Issue 7, 1996, Pages 855-864

  Chan, Candy K S ^a   Head, Geoffrey A ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

2 meth oxyidazoxan; Arterial blood pressure; Clonidine; Efaroxan; Heart rate; Imidazoline receptors; Moxonidine; Rilmenidine; methyldopa; 2 adrenoceptors

Indexed keywords

2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; CLONIDINE; EFAROXAN; IMIDAZOLINE RECEPTOR; METHYLDOPA; MOXONIDINE; RILMENIDINE;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BRADYCARDIA; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEART RATE; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0029971950     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199607000-00008     Document Type: Article

References (71)

1. Esler M, Zweifler A, Randall O, Julius S, de Quattro V: Agreement among three different indices of sympathetic nervous system activity in essential hypertension. Mayo Clin Proc 1977, 52:379-382.
2. Julius S, Weder AB: Brain and the regulation of blood pressure: a hemodynamic perspective. Clin Exp Hypertens [A] 1989, 11 (suppl 1): 1-19.
3. Anderson EA, Sinkey CA, Lawton WJ, Mark AL: Elevated sympathetic nerve activity in borderline hypertensive humans - evidence from direct intraneural recordings. Hypertension 1989, 14:177-183.
4. Bousquet P, Guertzenstein PG: Localization of the central cardiovascular action of clonidine. Br J Pharmacol 1973, 49:573-579.
5. Finch L, Haeusler G: Further evidence for a central hypotensive action of α-methyldopa in both the rat and cat Br J Pharmacol 1973, 47: 217-228.
6. Bousquet P, Feldman J, Schwartz J: Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines. J Pharmacol Exp Ther 1984, 230:232-236.
7. 2 adrenoceptor agonist. J Pharmacol 1985, 16: 259-278.
8. van Zwieten PA, Thoolen MJMC. Jonkman FAM, Wilffert B, de Jonge A, Timmermans PBMWM: Central and peripheral effects of S 3341 [(N-dicyclopropylmethyl)-amino-2-oxazoline] in animal models. Arch Int Pharmacodyn Ther 1986, 279:130-149.
9. 2-adrenoceptor agonist rilmenidine. Am J Cardiol 1988, 61 (suppl 7):6D-14D.
10. Armah BI, Hofferber E, Stenzel W: General pharmacology of the novel centrally acting antihypertensive agent moxonidine. Arzneimittel Forschung Drug Res 1988, 38:1426-1434.
11. 2-receptor selectivity and specificity of the antihypertensive agent moxonidine. Arzneimittel Forschung Drug Res 1988, 38:1435-1442.
12. 2-autoreceptors are involved in the blood pressure-lowering effects of moxonidine. J Cardiovasc Pharmacol 1990, 16:15-22.
13. Bricca G, Dontenwill M, Molines A, Feldman J, Tibirica E, Belcourt A, et al.: Rilmenidine selectivity for imidazoline receptors in human brain. Eur J Pharmacol 1989, 163:373-377.
14. Gomez RE, Ernsberger P, Feinland G, Reis DJ: Rilmenidine lowers arterial pressure via imidazole receptors in brainstem C1 area. Eur J Pharmacol 1991, 195:181-191.
15. 1-imidazoline receptors. J Cardiovasc Pharmacol 1992, 20 (suppl 4): S1-S10.
16. 1-imidazoline sites. J Pharmacol Exp Ther 1993, 264: 172-182.
17. Planitz V: Crossover comparison of moxonidine and clonidine in mild to moderate hypertension. Eur J Clin Pharmacol 1984, 27:147-152.
18. Ostermann G, Brisgand B, Schmitt J, Fillastre JP: Efficacy and acceptability of rilmenidine for mild to moderate systemic hypertension. Am J Cardiol 1988, 61 (suppl 7):76D-80D.
19. Fillastre JP, Letac B, Galinier F, le Bihan G, Schwartz J: A multicentre double blind comparative study of rilmenidine and clonidine in 333 hypertensive patients. Am J Cardiol 1988, 61 (suppl 7):81D-85D.
20. 1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience. J Cardiovasc Pharmacol 1994, 24 (suppl 1):S39-S48.
21. 2-adrenoceptors in the ventrolateral medulla. Eur J Pharmacol 1987, 134:1-13.
22. Ernsberger P, Guiliano R, Willette RN, Reis DJ: Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther 1990, 253:408-418
23. Bricca G, Dontenwill M, Molines A, Feldman J, Belcourt A, Bousquet P: The imidazoline-preferring receptor: binding studies in bovine, rat and human brainstem.Eur J Pharmacol 1989, 162:1-9.
24. 3H]RX 821 002 (2-methoxy idazoxan) in the human and rat brains. J Pharmacol Exp Ther 1993, 264:1187-1197.
25. 3H]-clonidine to identify imidazoline receptors in the rabbit brainstem. Br J Pharmacol 1993, 110: 1537-1543.
26. 3H]clonidine. Eur J Pharmacol Molec Pharm 1994, 266:25-33.
27. 2-adrenoceptors in the human central nervous system. Neuroscience 1994, 59:589-598.
28. 2-adrenergic receptors in the rostral ventrolateral medulla. J Hypertens 1988, 6 (suppl 4):s554-s557
29. 1-imidazoline and alpha(2)-adrenergic receptors in the antihypertensive responses evoked by central administration of clonidine analogs in conscious spontaneously hypertensive rats J Pharmacol Exp Ther 1995, 273:1162-1171
30. Michel MC, Insel PA: Are there multiple imidazoline binding sites Trends Pharmacol Sci 1989, 10:334-342
31. Wikberg JES, Uhlen S: Further characterization of the guinea pig cerebral cortex idazoxan receptor: solubilization, distinction from the imidazole site, and demonstration of cirazoline as an idazoxan receptor-selective drug. J Neurochem 1990, 55:192-203.
32. Coupry I, Limon I, Tesson F, Lachaud V, Gargalidismoudanos C, Parini A: The imidazoline-guanidinium receptive site - a subtype of imidazoline receptors. Therapie 1992, 47:519-524.
33. 2-type receptors: pharmacological characterization and relationship to monoamine oxidase. Br J Pharmacol 1993, 109:625-631.
34. Punnen S, Urbanski R, Krieger AJ, Sapru HN: Ventrolateral medullary pressor area: site of hypotensive action of clonidine. Brain Res 1987 422:336-346.
35. Tibirica E, Feldman J, Bousquet P: Differences in the ability of yohimbine to antagonize the hypotensive effect of clonidine in normotensive and spontaneously hypertensive anaesthetized rats. J Pharmacol Exp Ther 1988, 244:1062-1066
36. Feldman J, Tibirica E, Bricca G, Dontenwill M, Belcourt A, Bousquet A: Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit. Br J Pharmacol 1990, 100:600-604.
37. Tibirica E, Feldman J, Mermet C, Conon F, Bousquet P: An imidazoline-specific mechanism for the hypotensive effect of clonidine: a study with yohimbine and idazoxan. J Pharmacol Exp Ther 1991, 256: 606-613.
38. 2-adrenoceptor sites? Clin Exp Hypertens [A] 1992, 14:815-835.
39. Head GA, Godwin SJ, Sannajust F: Differential receptors involved in the cardiovascular effects of clonidine and rilmenidine in conscious rabbits. J Hypertens 1993, 11 (suppl 5):s322-s323.
40. Mayorov D, Chernobelski M, Medvedev O: Sympathoinhibitory action of rilmenidine in conscious sinoaortically denervated rats. J Cardiovasc Pharmacol 1993, 22:314-320
41. Sannajust F, Head GA: Rilmenidine-induced hypotension involves imidazoline-preferring receptors in conscious rabbits. J Cardiovasc Pharmacol 1994, 23:42-50.
42. Chan CKS, Sannajust F, Head GA: Role of imidazoline receptors in the cardiovascular actions of moxonidine, rilmenidine and clonidine in conscious rabbits. J Pharmacol Exp Ther 1995, 276:411-420.
43. 2-adrenoceptors to the central cardiovascular effects of clonidine and S 8350 in anaesthetized rats. Clin Exp Pharmacol Physiol 1991, 18: 401-408.
44. Tibirica E, Feldman J, Bousquet P: Contribution of catecholaminergic neurons of the dorsomedial and ventrolateral medulla oblongata to the hypotensive effect of clonidine in spontaneously hypertensive rats - in vivo voltametric studies. J Hypertens 1992, 10:1327-1334.
45. 2-Adrenoceptor-mediated inhibition of bulbospinal barosensitive cells of rat rostral medulla. Am J Physiol 1993, 265:R1065-R1075.
46. 2-adrenoceptors. Br J Pharmacol 1993, 110: 1635-1639.
47. 2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 1993, 348:593-600.
48. Urban R, Szabo B, Starke K: Is the sympathoinhibitory effect of rilmenidine mediated by afpha-2 adrenoceptors or imidazoline receptors? J Pharmacol Exp Ther 1994, 270:572-578.
49. 2-adrenoceptors in the cardiovascular effects of moxonidine. Eur J Pharmacol 1995, 282: 19-28.
50. 3H]idazoxan bind to different sites on rabbit forebrain and kidney membranes. Eur J Pharmacol 1988, 146:345-348.
51. 2 adrenergic receptors and non-stereoselective sites in human and rabbit brain cortex membranes. Biochem Pharmacol 1989, 38:455-463.
52. Wikberg JES: High affinity binding of idazoxan to a non-catecholaminergic binding site in the central nervous system: description of putative idazoxan-receptor. Pharmacol Toxciol 1989, 64: 152-155.
53. 2A-adrenoceptors. Eur J Pharmcol 1989, 167: 95-104.
54. 3H]rauwolscine? A comparison of nine tissues and cell lines. J Pharmacol Exp Ther 1995, 273:1287-1294.
55. Head GA, Sannajust F: Importance of imidazoline receptors in the cardiovascular responses to clonidine and rilmenidine in conscious rabbits. Fundam Clin Pharmacol 1992, 6 (suppl 1):31s-43s.
56. Nijkamp FP, de Jong W: Conversion of α-methyldopa to α-methylnoradrenaline; an explanation for the central inhibitory effect of α-methyldopa on blood pressure and heart rate of rats. Neth J Med 1974, 17:304-305.
57. Goldberg MR, Se Tung C, Ring M, Oates JA, Gerkens JF, Robertson D: Evidence that α-methylpinephrine is an antihypertensive metabolite of α-methyldopa. Clin Exp Hypertens [A] 1982, 4 (4&5):595-604.
58. Louis WJ, Conway E, Summers R, Beart P, Jarrott B: Effects of methyldopa metabolites of amine transmitters and adrenergic receptors in rat brain. Hypertension 1984, 6:1140-1144.
59. Head GA, Korner PI, Lewis SL, Badoer E: Contribution of noradrenergic and serotonergic neurons to the circulatory effects of centrally acting clonidine and α-methyldopa in rabbits. J Cardiovasc Pharmacol 1983, 5: 945-953.
60. Badoer E, Head GA, Aberdeen JA, Korner PI: Localization of the main noradrenergic neuron groups in the pons and medulla of the rabbit and the importance of cathodal lesions for prolonged survival. J Neurosci Methods 1987, 19:11-27.
61. Head GA, Burke SL: Importance of central noradrenergic and serotonergic pathways in the cardiovascular actions of rilmenidine and clonidine. J Cardiovasc Pharmacol 1991, 18:819-826
62. Wallenstein S, Zucker CL, Fleiss JL: Some statistical methods useful in circulation research. Circ Res 1980, 47:1-9.
63. 3H] idazoxan sites [abstract]. Fundam Clin Pharmacol 1992, 6 (suppl 1):P22
64. 2-adrenoceptors. J Cardiovasc Pharmacol 1992, 20 (suppl 4):S16-S20.
65. Berridge TL, Doxey JC, Roach AG: Antagonism of clonidine induced hypotension and bradycardia by RX 781 094 and other α-adrenoceptor antagonists in the rat [abstract]. Br J Pharmacol 1982, 75:139P
66. 2-adrenoceptors. Br J Pharmacol 1983, 78:489-494.
67. 2-adrenoceptor antagonist: in vivo and in vitro studies in the rabbit Naunyn Schmiedebergs Arch Pharmacol 1983, 322:221-227.
68. 1-imidazoline receptors in the rostral ventrolateral medulla. J Cardiovasc Pharmacol 1994, 24 (suppl. 1):S1-S6.
69. Van Zwieten P, Thoolen MJM, Timmermans PBMWM: The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine. Hypertension 1985, 6 (suppl 11):S28-S33.
70. Badoer E, Head GA, Korner PI: Effects of intracisternal and intravenous α-methyldopa and clonidine on haemodynamlcs and baroreceptor-heart rate reflex properties in conscious rabbits. J Cardiovasc Pharmacol 1983, 5:760-767.
71. Head GA, Quail AW, Woods AL: Lesions of A1 noradrenergic cells affect AVP release and heart rate during hemorrhage. Am J Physicl 1987, 253 (Heart Circ Physiol 22):H1012-H1017.